Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01397695 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT01397695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01397695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Lead sponsor
University of California, San Diego
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
January 31, 2014
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia (hht)